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Abstract
Background. We examined demographic, clinical, and psychological characteristics of a large
cohort (n = 368) of adults with dissociative seizures (DS) recruited to the CODES randomised
controlled trial (RCT) and explored differences associated with age at onset of DS, gender, and
DS semiology.
Methods. Prior to randomisation within the CODES RCT, we collected demographic and
clinical data on 368 participants. We assessed psychiatric comorbidity using the Mini-
International Neuropsychiatric Interview (M.I.N.I.) and a screening measure of personality
disorder and measured anxiety, depression, psychological distress, somatic symptom burden,
emotional expression, functional impact of DS, avoidance behaviour, and quality of life. We
undertook comparisons based on reported age at DS onset (<40 v. ⩾40), gender (male v.
female), and DS semiology (predominantly hyperkinetic v. hypokinetic).
Results. Our cohort was predominantly female (72%) and characterised by high levels of
socio-economic deprivation. Two-thirds had predominantly hyperkinetic DS. Of the total,
69% had ⩾1 comorbid M.I.N.I. diagnosis (median number = 2), with agoraphobia being
the most common concurrent diagnosis. Clinical levels of distress were reported by 86%
and characteristics associated with maladaptive personality traits by 60%. Moderate-to-severe
functional impairment, high levels of somatic symptoms, and impaired quality of life were also
reported. Women had a younger age at DS onset than men.
Conclusions. Our study highlights the burden of psychopathology and socio-economic
deprivation in a large, heterogeneous cohort of patients with DS. The lack of clear differences
based on gender, DS semiology and age at onset suggests these factors do not add substantially
to the heterogeneity of the cohort.
Introduction
Dissociative seizures (DS) are paroxysmal episodes of apparent altered responsiveness or tran-
sient loss of consciousness. They may be mistaken for epilepsy or syncope but are not accom-
panied by ictal encephalographic markers of epilepsy or physiological changes explaining
unconsciousness or other associated paroxysmal behavioural and experiential alterations.
The diagnostic gold standard is video-encephalographic (video-EEG) recording of typical
events but it is widely recognised that proof of the diagnosis cannot always be obtained and
that it may be entirely appropriate to commence treatment in the absence of diagnostic cer-
tainty (LaFrance, Baker, Duncan, Goldstein, & Reuber, 2013). Also referred to as ‘psychogenic
non-epileptic seizures’, ‘non-epileptic seizures’, ‘Non-Epileptic Attack Disorder’ (NEAD),
‘functional seizures’ and the pejoratively-laden ‘pseudoseizures’, DS are classified as dissocia-
tive and functional neurological disorders within ICD-10 (World Health Organisation, 1992)
and DSM-5 (American Psychiatric Association, 2013), respectively. The incidence of DS has
recently been estimated as ∼4.9/100 000/year (Duncan, Razvi, & Mulhern, 2011). Prevalence
estimates vary from 2 to 50/100 000 (Benbadis & Hauser, 2000; Kanemoto et al., 2017).
Psychiatric comorbidities, such as depression, anxiety, personality disorder, and post-trau-
matic stress disorder are common in patients with DS (Bermeo-Ovalle & Kanner, 2018; Brown
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& Reuber, 2016). Reported rates vary across studies, possibly
affected by inclusion criteria and assessment methods. Patients
with DS often report comorbid somatic symptoms (e.g. pain) or
additional functional neurological symptoms (McKenzie, Oto,
Graham, & Duncan, 2011), and characteristically have an avoi-
dant coping style and high levels of avoidance behaviour
(Dimaro et al., 2014; Goldstein & Mellers, 2006; Goldstein,
Drew, Mellers, Mitchell-O’Malley, & Oakley, 2000). Quality of
life is lower in patients with DS than in those with epilepsy
(e.g. Szaflarski et al., 2003). Long-term outcome, in terms of
chronic disability and welfare dependency, is poor in about 70%
of patients (Reuber, 2005) emphasising the need for evidence-
based treatments (Martlew, Pulman, & Marson, 2014).
It is well accepted that most adults with DS are women (Gates,
2002). There are conflicting findings with respect to gender differ-
ences and psychiatric comorbidity of DS. Lower rates of psychi-
atric diagnosis and chronic pain (Thomas & Bujarski, 2013)
and greater psychopathology (Holmes et al., 2001) have both
been reported in men. Myers, Trobliger, Bortnik, & Lancman
(2018) reported that men showed greater depression and a
more avoidant coping style. In other research, no gender differ-
ences were found in current or previous use of mental health ser-
vices and rates of other medically unexplained symptoms or panic
attacks, although women were more likely to have a history of
self-harm (Oto, Conway, McGonigal, Russell, & Duncan, 2005).
The onset of DS generally occurs before age 40 (Francis &
Baker, 1999) but older people may develop the disorder nonethe-
less (Behrouz, Heriaud, & Benbadis, 2006; Duncan, Oto, Martin,
& Pelosi, 2006). It has been suggested that there may be a different
gender ratio and likely range of precipitant factors in older
patients (Duncan et al., 2006). Patients developing DS over the
age of 55 were more likely to be male, less likely to report previous
sexual abuse, but more likely to report health-related traumatic
experiences in one particular study (Duncan et al., 2006); in addi-
ton, there was a trend towards better mental health in the later
onset subgroup. We have recently demonstrated that earlier age
at DS onset is largely seen in women while men appear likely
to develop DS at any age (Goldstein et al., 2019).
Approximately two-thirds of DS have a hyperkinetic semi-
ology, and one-third hypokinetic (Meierkord, Will, Fish, &
Shorvon, 1991; Reuber et al., 2003). Semiology is broadly compar-
able across cultures, genders, and age groups (Alessi & Valente,
2013; Asadi-Pooya & Emami, 2013; Korucuk, Gazioglu,
Yildirim, Karaguzel, & Velioglu, 2018; Oto et al., 2005; Thomas
& Bujarski, 2013; Wadwekar, Nair, Murgai, Thirunavukkarasu,
& Thazhath, 2014). Convulsive DS may be more common in
patients reporting antecedent sexual abuse (Selkirk, Duncan,
Oto, & Pelosi, 2008).
Here we present the baseline characteristics of a large UK
cohort of patients with DS recruited for a fully powered multi-
centre, pragmatic, parallel arm, randomised controlled trial
(RCT) to compare clinical and cost-effectiveness of Cognitive
Behavioural Therapy (CBT) for patients with DS plus standar-
dised medical care (SMC) v. SMC alone (Goldstein et al., 2015;
Robinson et al., 2017). The large number of clinical centres
involved in this prospective study avoids biases from smaller,
single-centre studies. Some earlier measures on these patients
have been reported elsewhere, along with all other patients who
were initially consented to the screening phase of the RCT
(Goldstein et al., 2019). We employed a wide range of measures
in our RCT population, some of which had not previously been
used in people with DS. Our current research questions were:
(1) what are the demographic, clinical, and psychological charac-
teristics of this large DS cohort?; (2) do their psychological char-
acteristics differ according to: (i) whether age at onset of DS was
before or after age 40; (ii) gender; or (iii) seizure semiology?
Methods
Recruitment into the study
Study recruitment was a two-stage process (Goldstein et al., 2015).
Adult patients (⩾18 years old) with DS were initially recruited
into a screening stage from neurology/specialist epilepsy clinics
across 27 National Health Service (NHS) Trusts in England,
Scotland and Wales. The main inclusion criteria were: the ability
to give informed consent; DS occurring within the previous 8
weeks; DS confirmed by video-EEG telemetry or clinical consen-
sus; no recorded history of intellectual disability; ability and will-
ingness to complete seizure diaries and questionnaire measures;
and willingness to be seen by a psychiatrist 3 months later.
Main initial exclusion criteria were: concurrent active epilepsy;
inability to complete seizure diaries or questionnaires; fulfilling
DSM-IV (American Psychiatric Association, 1994) criteria for
current drug/alcohol dependence; insufficiently fluent in English
to complete questionnaires or attend CBT without an interpreter;
or currently attending CBT for another condition that would not
have finished prior to the CODES psychiatric assessment. We also
excluded patients who had previously attended a CBT-based
treatment for DS at a participating study centre.
During the screening stage, participants provided demographic
information and then fortnightly data on DS frequency and sever-
ity, and were referred to the relevant study-affiliated psychiatry
service (one of 17 NHS Neuropsychiatry or Liaison Psychiatry
services) where, in addition to receiving a clinical psychiatric
assessment (Goldstein et al., 2015), eligibility for the RCT was
assessed. Criteria for trial eligibility (which, therefore, determined
the cohort reported here) were as per the screening phase, plus
these additional criteria: occurrence of DS in the 8 weeks preced-
ing the psychiatric assessment; willingness to continue to com-
plete seizure diaries and questionnaires, having provided regular
data on DS frequency after receiving their diagnosis in the screen-
ing phase; and willingness to attend weekly/fortnightly CBT ses-
sions. Randomisation had to be judged acceptable by the
patient and clinician in each case. Active psychosis, imminent
risk of self-harm, meeting DSM-IV criteria for current alcohol/
drug dependence, current benzodiazepine use exceeding the
equivalent of 10 mg diazepam/day, and existing diagnosis of fac-
titious disorder were exclusion criteria at this stage. Eligible
patients were consented; baseline measures, completed prior to
randomisation, are reported in this paper.
Over the two stages of the study, participants were recruited
between October 2014 and May 2017. Ethical approval for the
study was granted by NRES Committee London-Camberwell St
Giles (13/LO/1595). All participants gave written informed con-
sent. Figure 1 shows the flow of participants through the two
recruitment phases. Only the pre-randomisation data for the
368 who subsequently participated in the RCT are presented here.
Measures
Demographics
We collected a wide range of clinical and demographic variables.
Some of these measures were collected at consent to the screening
2 Laura H. Goldstein et al.
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phase of the overall study (Goldstein et al., 2019) and some were
collected immediately pre-randomisation. We also recorded the
Index of Multiple Deprivation (IMD) which gives a postcode-based
measure of deprivation by locality, using the databases that were
applicable when data collection commenced (Ministeries of
Housing Communities and Local Government, 2010; Scottish
Government, 2012; Welsh Government, 2011). These assess depriv-
ation using weighted domains (seven for the English and Scottish
IMDs, eight for the Welsh); here we report data separately for
each region with IMD scores converted into quintiles.
Clinicians rated whether DS semiology was predominantly
hyperkinetic or hypokinetic, and whether the person had a
previous diagnosis of epilepsy, and if so: whether they still had
epilepsy (but without having had a seizure in the past year);
whether they now had DS alone; and whether the previous diag-
nosis of epilepsy might have been incorrect, or could not be veri-
fied from medical records.
Healthcare use and costs of this group will be considered
elsewhere.
DS occurrence
The pre-randomisation measure of DS frequency was DS occur-
rence over the 4 weeks prior to psychiatric assessment
(Robinson et al., 2017) with subjective severity of DS, and how
Fig. 1. Study Flowchart up to randomisation. N.B. Characteristics of the 698 for whom baseline assessments were collected for Phase 1 have been reported by
Goldstein et al. (2019). In addition, variables predicting which of the 698 participants did not attend psychiatry appointments have been reported by Stone
et al. (2020).
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bothersome they were, rated using the Seizure Severity Scale
(Cramer, Baker, & Jacoby, 2002).
We administered measures to assess psychiatric comorbidities,
psychological distress and symptoms, psychosocial functioning,
heath-related quality of life, and beliefs about the DS diagnosis.
These are described in detail in Table 1.
Statistical analysis
To describe our cohort of patients with DS, we summarised
demographic, clinical, and psychological characteristics by using
means (S.D.), medians (IQR) and frequencies (%), where appropri-
ate. For clinical scales, established cut-offs and categories of sever-
ity were reported if they were available, as well as the overall
scores. For the SAPAS-SR score, a bar graph was used to illustrate
frequencies of responses according to Germans, Van Heck,
Moran, and Hodiamont (2008)’s three personality trait clusters.
To address objective 2 we investigated univariate associations
between age at onset of DS (<40 years v. ⩾40), gender (male v.
female), and predominant seizure type (hypokinetic v. hyperkin-
etic), as well as associations between these binary variables separ-
ately and: current M.I.N.I. diagnoses (none v. any); previous
M.I.N.I. diagnoses (none v. any); M.I.N.I. diagnosis of post-
traumatic stress disorder (PTSD), a proxy measure for significant
trauma history; scores on SAPAS-SR, CORE-10, GAD-7, PHQ-9,
Modified PHQ-15, Beliefs About Emotions Scale, WSAS, and
Avoidance of People, Places and Situations (total); and self-report
of having previously sought psychiatric help (yes or no). In addition,
for binary age at onset of DS (<40 v. ⩾40) only, we investigated dif-
ferences in suicidality responses on the M.I.N.I. as a proxy measure
of self-harm, and M.I.N.I. diagnosis of current panic disorder.
Formal group comparisons for continuous variables were car-
ried out using t tests or Wilcoxon rank-sum tests, where appropri-
ate. Namely, the WSAS and Avoidance scores violated the
assumptions needed when running a t test, so the non-parametric
rank-sum test was used instead. Fisher’s exact test was used for all
binary (categorical) variables. Each set of comparisons (i–iii) were
adjusted for multiple testing by applying a conservative
Bonferroni correction (significance level of 5%/number of tests
performed to assess questions i–iii). For example, the 16 tests
relating to 2(i) were compared to an adjusted p value of
p < 0.003125 (0.05/16) to deem a significant result not a chance
finding. Research question 2(ii) was addressed by 13 tests and 2
(iii) consisted of 12 tests. p values have been reported prior to
Bonferroni adjustment. All analyses were conducted in Stata ver-
sion 15 (StataCorp, Texas).
Results
Demographic, clinical, and psychological characteristics of
patients with DS
Table 2 presents descriptive summaries of demographic and clin-
ical data for our cohort, with further variables summarised in
Table 3. Of our cohort, 266 (72%) were women. Median age
was 35 years, median age at DS onset was 29 years (IQR 19,
42), while modal age at onset was 19 years (three participants
could not specify when their disorder had started). Median dur-
ation of DS disorder before diagnosis was 3 years (IQR 1, 8)
although mean duration was 6.2 (S.D. 8.8) years.
In terms of IMD scores, over 50% of participants resided in
areas falling in the two highest deprivation quintiles (57% of
participants from England, 51% of those from Scotland, and
86% of those from Wales) as measured by an index of the general
population. The majority (56%) had completed secondary or
vocational education, two-thirds were not currently in employ-
ment or education and there were high rates of receipt of disability
benefits. Of the total, 40% reported having a carer who, in just
over half the cases, was their partner.
Median belief in the diagnosis of DS (measured at initial recruit-
ment) was 8 (IQR 7, 10), indicating strong belief in the diagnosis.
The majority of participants (n = 195; 53%) had received their
diagnosis on the basis of video-EEG. For cases where video-EEG
was not involved, or where a consensus diagnosis had not already
been obtained, a consensus rating was sought from one of two
neurologists within the project team. In total, 236 (65%) partici-
pants had predominantly hyperkinetic, and 130 (36%) predomin-
antly hypokinetic, DS; this information was not available for two
participants. A total of 101 participants (27%) reported they had
received a diagnosis of epilepsy and 76 (21%) that they were cur-
rently being prescribed AEDs. At a level only slightly below
patients’ self-report, clinicians judged that 89 (24%) participants
had received a previous diagnosis of epilepsy, but felt that around
half of these had been misdiagnosed, while for around an add-
itional third of these they considered it was impossible to deter-
mine the validity of this earlier diagnosis.
The majority (241; 65%) indicated they had previously sought
help for a mental health problem and, of the 365 responding, 261
(72%) reported currently suffering from another medical problem.
Psychiatric comorbidities
Data on M.I.N.I. diagnoses is shown in Table 4. In total, 255 par-
ticipants (69%) had at least one current M.I.N.I. diagnosis, and
247 (67%) at least one previous M.I.N.I. diagnosis. The median
number of current M.I.N.I. diagnoses was 2 (range 0–8) (see
Supplementary Table 1 for more detail). The five most common
current diagnoses (present in >20% of the sample; Table 3) were
Agoraphobia (44.8%), Major Depressive Disorder (31%),
Generalised Anxiety Disorder (29.3%), Post-traumatic Stress
Disorder (23.4%), and Social Phobia (Social Anxiety Disorder)
(20.4%). The most common past diagnosis was Major
Depressive Disorder (52.4%). Of the total, 63% met criteria for
suicidality and of these, 22.4% were judged high risk, although
none were felt to be at imminent risk of self-harm by their
study psychiatrist. A very small number were found to show sub-
stance dependence, not detected during the earlier assessment, on
the M.I.N.I.
On the SAPAS-SR (completed by n = 363) the mean score was
3.9 (S.D. 2.0; range 0–8) and 211 (58%) of the cohort had scores
suggesting maladaptive personality traits. Online Supplementary
Figure 1 shows the frequency of responses arranged in the three
clusters identified by Germans et al. (2008) as broadly corre-
sponding to Personality Clusters A, B, and C. Items most fre-
quently endorsed were: being a worrier, dependence on others,
and being a perfectionist (‘Cluster C’ items), whilst the least fre-
quently endorsed were ‘Cluster A’ items (not trusting others, dif-
ficulty making and keeping friends, and being a loner).
Measures of psychological distress and somatic symptom
burden
Table 3 shows scores on the CORE-10, GAD-7, PHQ-9 (with fur-
ther classifications of levels of severity in online Supplementary
Table 2) and the Modified PHQ-15. On the CORE-10, mean
total scores indicated moderate distress although most scores
4 Laura H. Goldstein et al.
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Table 1. Psychiatric and psychological assessment measures
Domain Scale Content
Psychiatric comorbidity Mini-International Neuropsychiatric Interview
(M.I.N.I. v6.0; (Sheehan et al., 1998)
Structured psychiatric diagnostic interview which requires mostly
yes/no answers. Comprises modules corresponding to diagnostic
categories standardised against DSM-IV; all but one (Antisocial
Personality) are from Axis I.
Standardised Assessment of Personality
Abbreviated Scale, Self-Report (SAPAS-SR)
(Germans et al., 2008).
8 questions ask about how the person sees themselves. Responses
are yes/no; scores range from 0-8; scores of ⩾4 indicate the
presence of personality disorder, which we interpret here as the
presence of maladaptive personality traits. Fifty per cent of
Germans et al.’s (2008) sample had received Axis II diagnoses on the
SCID-II; the SAPAS-SR was found to correctly classify 81% of their
sample. A three-factor structure was identified that broadly
corresponded to Cluster A, B, and C personality disorders.
Psychological distress and
somatic symptom burden
Generalised Anxiety Disorder Assessment (GAD-7)
(Spitzer, Kroenke, Williams, and Lowe, 2006).
7- item scale used to measure anxiety. Good test-retest reliability
and good criterion, construct, factorial and procedural validity.
Higher scores indicate higher levels of anxiety. Cut-off of 10
identifies cases of GAD.
Patient Health Questionnaire 9 (PHQ-9) (Kroenke,
Spitzer, and Williams, 2001).
9-item scale used to measure depression. High internal consistency
and high test-retest reliability. Scores range from 0 to 27. Higher
scores indicate more severe depression. Scores of ⩾10 are classified
as cases.
Clinical Outcomes in Routine Evaluation
(CORE-10) (Connell and Barkham, 2007).
10-item general measure of psychological distress (including risk).
Good internal consistency; concurrent validity with other measures
of depression, anxiety, and overall mental health. Higher scores
reflect greater distress. Scores between 0 and 10 = non-clinical
range; clinical range for distress is ⩾11.
Modified PHQ-15 (Carson et al., 2015). This asked participants whether they were “bothered a lot over the
previous month” by a range of symptoms. The scale incorporated
15 common symptoms with which patients present in primary care,
10 ‘neurological’ symptoms and five psychological symptoms taken
from the Prime MD Questionnaire. Higher total scores indicated
greater numbers of comorbid symptoms; we also considered the
frequency with which each symptom was reported.
Beliefs About Emotions Scale (BES; Rimes and
Chalder, 2010).
12-item scale measuring beliefs about the unacceptability of either
expressing or experiencing negative emotions. The scale is reliable
and valid. Each item is scored 0-6; total scores range from 0–72;
higher scores indicate stronger beliefs about the unacceptability of
negative emotions.
Psychosocial functioning
and functional impact
Work and Social Adjustment Scale (WSAS)
(Mundt, Marks, Shear, and Greist, 2002).
5-item scale measuring patients’ self-reported perceptions of the
functional impact DS had on their lives in the areas of work, home
management, social leisure and private leisure activities, family and
other relationships. Simple, valid measure of impaired functioning
with high internal consistency and high test–retest reliability.
Overall scores range from 0 to 40; higher scores indicate greater
impact. Scores >20 reflect moderately severe impairment (or
greater).
Avoidance of People, Places, and Situations Locally devised 3-item measure examining the avoidance of people,
activities (e.g. physical exertion, bathing unsupervised) and
situations (e.g. being out in public alone, social gatherings, using
public transport) due to fear of having a seizure, each rated 0 (Never
Avoid) to 10 (Always Avoid). Total possible score = 30. This scale has
a Cronbach’s alpha of 0.83, which shows good internal reliability
between the three questions.
Health-related quality of life
(HRQoL)
Short Form 12-item (version 2) Health Survey
(SF-12v2) (Ware, Kosinski, Turner-Bowker, and
Gandek, 2002).
12-item scale derived from the SF-36v2. Provides a measure of two
overall physical and mental health concepts: the Physical
Component Summary (PCS) and the Mental Component Summary
(MCS). These have high internal consistency (Cheak-Zamora,
Wyrwich, & McBride, 2009). A higher score on each measure
indicates better HRQoL. Summary scores are norm-based T scores
with an expected mean of 50 and standard deviation of 10.
Visual analogue scale from EQ-5D-5L (EuroQol
Research Foundation, 2009).
Person rates current health on a scale from 0 to 100; 0 = the worst
health the person can imagine and 100 = the best health the person
can imagine.
Beliefs about diagnosis Beliefs about Diagnosis scale Locally devised single item scale measuring participant’s belief that
they had been given the correct diagnosis of DS, on a single item
scale from 0 (not at all) to 10 (extremely strongly).
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Table 2. Demographic and clinical characteristics of the trial sample
n (%) N = 368
Age Mean (S.D.) 37.5 (14.3)
Median (IQR) 35 (25, 48)
[range] [18, 78]
Ethnicity White 330 (89.7)
Other (Asian, Black, Mixed or Other) 38 (10.3)
IMD score England (n = 284) 1. Least deprived 31 (10.9)
2 37 (13.0)
3 54 (19.0)
4 80 (28.2)
5. Most deprived 82 (28.9)
IMD score Scotland (n = 77) 1. Least deprived 10 (13.0)
2 15 (19.5)
3 13 (16.9)
4 16 (20.8)
5. Most deprived 23 (29.9)
IMD score Wales (n = 7) 1. Least deprived 1 (14.3)
2 0 (0.0)
3 0 (0.0)
4 1 (14.3)
5. Most deprived 5 (71.4)
Qualifications (n = 367) None 43 (11.7)
Secondary 89 (24.3)
Vocational 120 (32.7)
Further 56 (15.3)
Higher 59 (16.1)
Current employment (n = 365) Employed or in education 123 (33.7)
Not employed or in education 242 (66.3)
Receiving disability benefits if of working age (<65 years) and not working (n = 233) Yes 165 (70.8)
Receiving disability benefits if of working age (<65 years) and working (n = 110) Yes 18 (16.4)
Relationship status Single 149 (40.5)
Married/cohabiting 195 (53.0)
Separated/divorced 19 (5.2)
Widowed 5 (1.4)
Living arrangements Alone 52 (14.1)
With others 316 (85.9)
Has dependents Yes 121 (32.9)
Relationship of dependent(s)a (n = 121) Child 114 (94.2)
Other (Partner, parent or other) 15 (12.5)
Has a carer Yes 149 (40.5)
Relationship of carer(s)a (n = 149) Partner 78 (52.3)
Parent 35 (23.5)
Child 17 (11.4)
Other (Friend, paid or other) 52 (34.9)
(Continued )
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(over 86%) fell in the range likely to indicate clinically relevant
levels of distress (as scores from mild to severe are considered clin-
ically meaningful). Mean PHQ-9 scores suggested moderate
depression, with the majority (64%) classified as meeting the ‘case-
ness’ criterion. Mean GAD-7 scores were suggestive of moderate
levels of anxiety but over half the sample were classified as ‘cases’.
Figure 2 shows the reported frequency of Modified PHQ-15
symptoms. Unsurprisingly, DS occurrence was the most com-
monly reported symptom; the six next most commonly reported
symptoms were tiredness/low energy, headaches, trouble sleeping,
memory or concentration problems, generalised worrying and
pain in limbs or joints.
The Beliefs About Emotions Scale data indicated that partici-
pants reported greater negative beliefs (mean 41.9; S.D. 16.9;
n = 367) about the acceptability of experiencing and expressing
negative thoughts and feelings than reported for a group of
healthy controls comprising 67% females and mean age 37.6
years (mean score 27.9; S.D. 11.3; Rimes & Chalder, 2010).
Measures of psychosocial functioning and functional impact
The mean WSAS score was 22.7 (S.D. 10.5; n = 366), with a
median of 24 (IQR 15–31). Scores on the Avoidance of People,
Places, and Situations scale suggested slightly higher avoidance
of situations and activities than of people, as a result of fearing
Table 2. (Continued.)
n (%) N = 368
Belief in diagnosis score (n = 366) Mean (S.D.) 8.0 (2.2)
Median (IQR) 8 (7, 10)
[range] [0, 10]
Age at onset in years (n = 365) Mean (SD) 30.9 (14.1)
Median (IQR) 29 (19, 42)
[range] [1, 76]
Years with DS (n = 365) Mean (SD) 6.2 (8.8)
Median (IQR) 3 (1, 8)
[range] [0, 65]
Currently suffering from any other medical problem (n = 365) Yes 261 (71.5)
Previously diagnosed with epilepsy (self-report) Yes 101 (27.4)
Currently prescribed anti-epileptic drugs Yes 76 (20.7)
Monthly seizure frequency Median (IQR) 15 (4, 47)
[range] [0, 649]
Longest period of time without DS in last 6 months (consecutive days) (n = 367) Median (IQR) 7 (2, 21)
[range] [0, 119]
Seizure severity Mean (S.D.) 4.7 (1.6)
1 = not at all Median (IQR) 5 (4, 6)
7 = very severe [range] [1, 7]
Seizure bothersomeness Mean (S.D.) 5.3 (1.7)
1 = not at all Median (IQR) 6 (4, 7)
7 = very bothersome [range] [1, 7]
SAPAS-SR (n = 363) Maladaptive personality traits (⩾4) 211 (58.1)
CORE-10 Case (distress) (⩾11) 317 (86.1)
GAD-7 Case (anxiety) (⩾10) 191 (51.9)
PHQ-9 (n = 367) Case (depression) (⩾10) 236 (64.3)
SF-12v2 Physical Component Summary score (n = 366) Mean (S.D.) 39.7 (12.2)
[range] [13.4, 66.0]
SF-12v2 Mental Component Summary score (n = 366) Mean (S.D.) 37.8 (11.8)
[range] [13.4, 68.1]
EQ-5D-5L visual analogue scale (health today 1–100) (n = 363) Mean (S.D.) 55.5 (23.0)
[range] [1-100]
aTotals can add up to more than 100%.
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seizure occurrence. The mean and median total scores for
Avoidance were 17.6 (S.D. 9.0) and 20 (IQR 11–25), respectively,
out of a possible 30.
Health-related quality of life
Summary scores on the SF-12v2 (n = 366) showed mean Physical
Component Scores (PCS) of 39.7 (S.D. 12.2) and mean Mental
Component Scores (MCS) of 37.8 (S.D. 11.8). The mean rating
of current health on the EQ-5D-5L visual analogue scale (VAS)
was 50.9 (S.D. 23.1).
Differences in characteristics when age at onset <40 or ≥⍰40
Age at onset of DS was associated with gender: 77.7% (205/264) of
women were <40 at the onset of DS compared to 58.4% (59/101)
of men ( p < 0.001). Older age at DS onset was associated with
having no current M.I.N.I. diagnoses: 41.6% (42/101) of those
⩾40 at onset had none v. 26.5% (70/264) of those <40
( p = 0.007); and similarly for previous M.I.N.I. diagnoses: 40.6%
(41/101) v. 29.5% (78/264). A further breakdown of number of
M.I.N.I. diagnoses, split by age at onset, is given in online
Supplementary Table 1. In addition, the median WSAS score
for those aged <40 at onset of DS was 23 (IQR 14–30) compared
to 27 (IQR 18–32) for those ⩾40; p = 0.0306. However, only the
gender-specific differences remained significant after Bonferroni
correction (α = 0.0031).
Gender-specific differences in psychological characteristics
Men reported higher levels of avoidance behaviour and functional
impairment compared to women. On the Avoidance of People,
Places and Situations scale, the median total score for women
Table 3. Descriptive summaries for age of onset, gender, seizure type, and psychological variables
n (%) N = 368
Age at onset of DS (n = 365) <40 264 (72.3)
⩾40 101 (27.7)
Sex Female 266 (72.3)
Male 102 (27.7)
Predominant seizure type (n = 366) Hyperkinetic 236 (64.5)
Hypokinetic 130 (35.5)
Current M.I.N.I. diagnosis One or more 255 (69.3)
None 113 (30.7)
Previous M.I.N.I. diagnosis One or more 247 (67.1)
None 121 (32.9)
SAPAS-SR score (maladaptive personality traits) (n = 363) Mean (S.D.) 3.9 (2.0)
[range] [0, 8]
CORE-10 score (distress) Mean (S.D.) 18.2 (6.5)
[range] [4, 34]
GAD-7 score (anxiety) Mean (S.D.) 9.8 (6.2)
[range] [0, 21]
PHQ-9 score (depression) Mean (S.D.) 12.4 (6.6)
[range] [0, 27]
Modified PHQ-15 total (somatic symptoms) Mean (S.D.) 16.7 (6.5)
[range] [2, 30]
Beliefs About Emotions score (n = 367) Mean (S.D.) 41.9 (16.9)
[range] [0, 72]
Work and Social Adjustment Scale (n = 366) Mean (S.D.) 22.7 (10.5)
Median (IQR) 24 (15, 31)
[range] [0, 40]
Avoidance of People, Places, and Situations (total) Mean (S.D.) 17.6 (9.0)
Median (IQR) 20 (11, 25)
[range] [0, 30]
Ever sought medical help for a mental health problem Yes 241 (65.5)
No 127 (34.5)
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was 18 (IQR 10–25; n = 266), and for men 22 (IQR 14–27;
n = 102); p = 0.009 (Wilcoxon rank-sum). On the WSAS, the
median score for women was 23 (IQR 14–30; n = 265) and for
men 27 (IQR 17–33; n = 101); p = 0.042. Neither of these findings
remained significant after adjusting for multiple testing
(α = 0.0039).
Differences in psychological characteristics relating to seizure
semiology
There were no differences in psychological characteristics between
patients with predominantly hyper- or hypokinetic DS.
Discussion
We report data from 368 patients with DS recruited for a multi-
centre RCT, allowing a detailed study of psychopathology and its
relationship to demographic and clinical variables in a large, well-
characterised cohort.
Although we did not collect detailed data about psychiatric
comorbidity on the 698 people initially entering the study, basic
demographics of the cohort (N = 368) reported here were similar
to the larger group of 698 patients initially recruited into the
CODES study (Goldstein et al., 2019). Furthermore, the general-
isability of the sample reported here is supported by the observa-
tion that there were no significant differences in clinical and
demographic variables between 568 of this initial group who
attended a psychiatric assessment (and whose further eligibility
was therefore considered for the RCT), compared to 130 who
did not (Stone et al., 2020). In addition, we have recently
shown (Goldstein et al., in press) that the 368 people reported
here did not differ on key characteristics from the 58 people
eligible for the RCT but who ultimately did not participate
(see Fig. 1).
In the current cohort, median age at the onset was in adult-
hood although the distribution was skewed with modal onset at
19 years, with a duration of symptoms comparable to other stud-
ies (Asadi-Pooya & Sperling, 2015). Over half had received their
diagnosis based on video-EEG recordings. Although around a
quarter of the cohort had received a previous diagnosis of epi-
lepsy, clinicians cast doubt on the accuracy of over 80% of these
diagnoses, supporting previous accounts of frequent misdiagnosis
in this patient group (Reuber, Fernandez, Bauer, Helmstaedter, &
Elger, 2002).
Where diagnosis was not based on video-EEG but on clinical
consensus, we acknowledge the possibility of misdiagnosis. In
addition, we excluded participants with known epileptic seizures
in the previous 12 months. Nevertheless, given the known limita-
tions of diagnosis by seizure semiology (Syed et al., 2011) it is pos-
sible that some patients with active epilepsy were included despite
our consensus review process, so the possibility of misdiagnoses is
a limitation of the study.
Table 4. Numbers and percentages of sample attaining diagnoses on the Mini-International Neuropsychiatric Interview
n (%) N = 368
n
(%) N = 368
Major depressive disorder (current) Yes 114 (31.0) Post-traumatic stress disorder (current)a Yes 86 (23.4)
Major depressive disorder (past) Yes 193 (52.4) Alcohol dependence (current) Yes 4 (1.1)
Suicidalitya Yes 232 (63.0) Alcohol abuse (current) Yes 5 (1.4)
Suicidality risk level (n = 232) Low (1-8) 151 (65.1) Substance dependence (current)b Yes 2 (0.5)
Mod (9-16) 29 (12.5) Substance abuse (current)c Yes 1 (0.3)
High (≥17) 52 (22.4) Psychotic disorder (current) Yes 10 (2.7)
Bipolar I disorder (current) Yes 4 (1.1) Psychotic disorder (lifetime) Yes 21 (5.7)
Bipolar I disorder (past) Yes 22 (6.0) Mood disorder with psychotic features
(lifetime)
Yes 19 (5.2)
Bipolar II disorder (current) Yes 3 (0.8) Mood disorder with psychotic features
(current)
Yes 11 (3.0)
Bipolar II disorder (past) Yes 10 (2.7) Anorexia Nervosa (current) Yes 0 (0.0)
Bipolar disorder NOS (current) (n = 367) Yes 3 (0.8) Bulimia Nervosa (current) Yes 13 (3.5)
Bipolar disorder NOS (past) (n = 366) Yes 6 (1.6) Anorexia Nervosa [Binge eating/purging]
(current)
Yes 0 (0.0)
Panic disorder (lifetime) Yes 106 (28.8) Generalised anxiety disorder (current) Yes 108 (29.3)
Panic disorder (current)a Yes 57 (15.5) Antisocial personality disorder (lifetime) Yes 16 (4.3)
Social Phobia [social anxiety disorder]
(current)
Yes 75 (20.4) Agoraphobia (current) Yes 165 (44.8)
Obsessive compulsive disorder (current) (n
= 367)
Yes 34 (9.3)
NOS = not otherwise specified.
aUsed in analyses to test for associations (objectives 2i-iii).
bSubstance = cannabis (n = 2).
cSubstance = cannabis (n = 1).
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Most of the patients lived in areas characterised by high levels of
deprivation, extending previous findings from Scotland to the wider
UK (Duncan, Oto, & Wainman-Lefley, 2012). Unemployment and
economic inactivity were common. For those of working age but
not working, almost three-quarters were in receipt of state financial
disability benefits, a factor reported by others (McKenzie, Oto,
Russell, Pelosi, & Duncan, 2010) to predict poor outcome.
Interpretation of these findings is limited by the fact that our
study did not allow us to compare our data with that from patients
with other neurological or psychiatric conditions, and we cannot say
whether other confounding factors might contribute to this pattern
of socio-economic deprivation; nevertheless, at a population level,
the findings demonstrate considerable socio-economic deprivation
and benefit dependency in our sample, which may be relevant to
access, uptake and response to interventions.
We acknowledge that the scales and questionnaires used in the
study cannot be assumed to definitively diagnose psychiatric con-
ditions, although they may strongly suggest them. Nevertheless,
the consistently high scores seen across a range of measures sug-
gest a high degree of psychiatric morbidity within the cohort,
involving multiple different categories, primarily affective, anx-
iety, and personality disorders. Elsewhere, using an earlier version
of the M.I.N.I. with DS patients, Mökleby et al. (2002) found a
mean of 1.9 DSM-IV diagnoses with 91% of patients having at
least two comorbid psychiatric diagnoses; our cohort had a simi-
lar mean of 1.9 (S.D. 1.9) and median of 2 (IQR 0–3) M.I.N.I. diag-
noses. In our cohort 187/368 (51%) had two or more current
M.I.N.I. diagnoses, most commonly anxiety disorders (i.e. agora-
phobia, generalised anxiety disorder, social anxiety) as well as
PTSD and depression, a profile similar to that reported by
other studies (Bermeo-Ovalle & Kanner, 2018). However, the
fact that some patients with more severe psychiatric comorbidities
were excluded from the study on clinical grounds may mean that
the rates of comorbidity in our sample are a little lower than in
groups of DS patients seen in routine clinical practice.
Just under half the cohort reported symptoms suggestive of
agoraphobia, which commonly develops in DS in relation to
fear of having a seizure in public. Although standard psychiatric
classification links agoraphobia to panic disorder, our data suggest
that only 15.5% of the cohort would currently meet diagnostic cri-
teria for the latter condition. This is about a third of the number
with likely agoraphobia. This disparity is consistent with a model
of dissociative seizures in which the seizures are viewed as a dis-
sociative response to arousal in some ways analogous to panic
attacks (Goldstein & Mellers, 2006). Such patients may have
many features predisposing to panic disorder but since they do
not experience panic per se, that diagnosis will not apply to
them. Indeed, our previous work indicated that patients with
DS experience autonomic symptoms of arousal in the absence
of subjective awareness of feelings of panic (‘panic without
panic’; Goldstein & Mellers, 2006).
Other symptom data suggest a prevalence of 31% for current
major depressive disorder, and 23.4% for PTSD, within the
range cited elsewhere (e.g. Bermeo-Ovalle & Kanner, 2018). In
terms of questionnaire measures of psychological distress,
between 52% and 86% of the sample were ‘cases’ (online
Supplementary Table 1), depending on the specific measure, the
highest value being for the most general measure, the CORE-10.
Given the well-established association between DS and a history
of trauma or abuse, a high rate of PTSD is perhaps unsurprising.
However, in the experience of the authors, it is unusual for
patients with DS to have been given a formal diagnosis of
PTSD, even when they have had a specialist psychiatric assess-
ment. This may be because the seizures themselves, and their
Fig. 2. Occurrence of reported symptoms on the Modified PHQ-15. Occurrence of somatic symptoms reported on the Modified PHQ-15, illustrated in order of fre-
quency of ‘yes’ responses: ‘During the past month have you been bothered a lot by [symptom]?’ The vertical dashed line indicates the number of participants who
responded to the questionnaire overall (n = 364).
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psychosocial antecedents, tend to be the focus of assessment, such
that other psychiatric symptoms may not be fully explored. The
data also showed that 31% of patients had no concurrent psychi-
atric disorder detected on the M.I.N.I., emphasising the need to
see other psychiatric comorbidities as common but not necessary
for the development of DS.
On the SAPAS-SR, we found that 58% scored at or above the
cutoff suggestive of maladaptive personality traits. We did not
conduct clinical interviews to verify a diagnosis of personality dis-
order in this study, so cautious interpretation is needed here. Prior
work suggests DS patients have higher rates of Cluster B person-
ality disorders (antisocial, borderline, narcissistic, histrionic) than
Cluster C (avoidant, dependent, obsessive-compulsive) disorders,
with Cluster A disorders (schizoid, schizotypal, paranoid) least
common (Bermeo-Ovalle & Kanner, 2018). Our sample most fre-
quently endorsed items relating to worry and perfectionism, char-
acteristic of Cluster C disorders, while least frequently endorsing
items relating to difficulty making and keeping friends and being
a loner. It may be that these results reflect the confounding effect
of other psychiatric morbidity, in particular anxiety disorders
which were common in our sample. Of note, the mean
SAPAS-SR score in our study (3.9, S.D. 2.0) is comparable to
that reported for a sample of patients with Generalised Anxiety
Disorder (mean 3.8, S.D. 2.03; Mahoney, Hobbs, Newby,
Williams, & Andrews, 2018). The Cluster C characteristics seen
in our cohort are transdiagnostic processes which are targetable
and could be included in future cognitive behavioural approaches.
Our cohort reported at least moderately severe functional
impairment, similar to that reported elsewhere (Mayor et al.,
2013), together with appreciable levels of avoidance of daily activ-
ities as a result of their DS, consistent with previous reports from
our group and others (Goldstein & Mellers, 2006; Hixson, Balcer,
Glosser, & French, 2006). Our participants also held particularly
negative beliefs about experiencing and expressing emotions, with
scores consistent with high levels of emotional avoidance. Taken
together, these findings support our fear-avoidance therapeutic
model for DS patients (Goldstein et al., 2015) and suggest that
third wave psychotherapy could be an alternative to DS-specific
CBT.
Health-related quality of life scores (SF-12v2) were low for
both the physical and mental health composite scores, while a sin-
gle rating of self-reported overall health from the EQ-5D-5L VAS
suggested a particularly negative sense of general health, given
that expected values in the UK are in the order of 80 (Janssen,
Szende, Cabases, Vilagut, & König, 2019). Our participants
reported a range of somatic symptoms on the Modified
PHQ-15 which, with the exception of DS, were generally similar
to those reported by a broader sample of neurology outpatients
with symptoms unexplained by disease (Carson et al., 2015).
Our large sample allowed us to investigate the demographic
and clinical correlates of psychiatric comorbidity. Overall, we
identified a few gender- or age-related differences. Women were
associated with an earlier age at onset of DS (<40) compared to
men; this is the only finding that remains statistically significant
after Bonferroni correction. Male participants demonstrated
higher levels of avoidance behaviour and functional impairment
due to their DS, while older age at onset patients had less severe
psychopathology (fewer current M.I.N.I. diagnoses); however,
these differences were no longer significant following correction
for multiple testing. Thus, while there is a suggestion that older
onset (and male) individuals with DS may have different psycho-
logical profiles, our findings fell short of statistical significance
after using stricter adjustments than those used elsewhere
(Duncan et al., 2006). We found no evidence for differences in
psychological characteristics between patients with predominantly
hyper- or hypokinetic DS.
In terms of limitations, we recognise that this study was con-
ducted within the context of a large RCT and our inclusion and
exclusion criteria may have selectively removed individuals with
more severe comorbidity as well as those not wanting to be
randomised. We excluded people with active epilepsy but some
with inactive epilepsy did take part. Video-EEG was not uni-
formly used to diagnose patients, but the study was undertaken
in the context of a pragmatic RCT and video-EEG is not uni-
formly/quickly available in all health service settings; if a consen-
sus diagnosis had not already been obtained, a subsequent expert
review of diagnosis was held when video-EEG had not been
undertaken. Of note, the majority of patients held a strong belief
in diagnosis, perhaps related to the verbal and written informa-
tion relayed to patients in the study as part of the delivery of
their diagnosis (Goldstein et al., 2015) which may not be typical
of DS patients more widely.
The current study indicates the heterogeneity of psychopath-
ology in a large UK sample of DS patients which may have impli-
cations for the outcome of a psychotherapeutic intervention, the
findings of which will be reported elsewhere. Future consideration
of the impact of such characteristics with respect to treatment will
help to guide future treatment approaches and service provision
in this area.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291720001051.
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